FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved a supplemental New Drug Application (sNDA) for EMEND®
(aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor
antagonist.
Language:
English
Contact:
MerckMedia:Doris Li, 908-740-1903An Phan, 908-255-6325orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Merck | Neurology | New Drug Applications | Pediatrics | Pharmaceuticals